DaVita: I Believe This Is Overvalued

DaVita (DVA) has more than doubled over six months following a strong Q1 ’26 earnings beat and a favorable court ruling. The article expects 2026E AEPS recovery of 30%+ with 10–16% annualized growth through 2028, but notes the stock’s run left valuation above ~$210/share versus a $130 fair value target, prompting the author to sell 95%+ of their position.

Analysis

The market is now paying for de-risking, not acceleration. That matters because the earnings recovery already embedded in estimates is substantial, so the next leg requires either faster unit growth or a permanent step-up in the valuation multiple. In the near term, this looks like a sentiment-driven rerate that can persist for a few weeks, but once the legal overhang fades from headlines, the stock will trade back on reimbursement, volume mix, and buyback math rather than courtroom optics.

The second-order winner is any cheaper, similarly exposed healthcare-services name with less momentum baggage; relative-value investors will eventually migrate toward names where growth is not already capitalized at a premium. For DVA specifically, the biggest risk to shorts is that a clean legal outcome can reset the market’s terminal multiple higher than historical averages, especially if management uses buybacks to support EPS optics. The bigger medium-term risk is that reimbursement and patient-mix trends fail to confirm the 2026E recovery, which would force multiple compression from an already elevated base.

Contrarianly, the consensus may be underestimating how sticky a court-driven rerating can be in a low-growth healthcare asset. But that only holds if subsequent prints validate the recovery; otherwise this becomes a classic multiple-over-earnings trade where the stock outruns the fundamentals by several quarters. The thesis is falsified if the next two earnings updates show above-plan AEPS progression, no reimbursement headwind, and sustained capital return that keeps consensus moving up faster than price.

Key Decisions for Investors

• Initiate a tactical short DVA on strength, ideally after momentum cools, with a 1-3 month horizon; risk/reward is attractive only if the stock remains >20% above a reasonable fair-value band and the next earnings print does not materially raise 2026E EPS.
• Prefer a defined-risk bearish structure over an outright short: buy 3-6 month DVA put spreads to capture valuation mean reversion while limiting squeeze risk if the legal overhang continues to compress.
• Run a relative-value pair: short DVA / long a cheaper healthcare-services proxy or sector basket (e.g., XLV) to isolate multiple compression from beta; the trade works best if the market keeps rewarding de-risking but not further estimate upgrades.
• Set a catalyst alert around the next guidance update and reimbursement commentary; if management does not convert the 30%+ AEPS recovery into incremental estimate revisions, add to the bearish position.